Roche gets early appeal on Taq patents:
This article was originally published in Clinica
Executive Summary
Roche has persuaded a US appeal court to consider separately two of its PCR patents that were challenged in a federal district court decision in favour of Promega. According to Roche, Promega's actions directly infringed two US PCR patents, 4,638,195 and 4,683,202 and Promega's actions to induce others to use the native Taq enzyme for PCR procedures indirectly infringed the PCR patents. In December Promega won a decision against Roche concerning natural Taq which Promega claimed could have jeopardised Roche's entire PCR patent portfolio (see Clinica No 888, p 7).